*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Prerequisites of Pharmacological Consideration with the case of Liver Ischemia reperfusion injury

Author: ALLA , MIKHAIL V. POKROVSKIY, KONSTANTIN S. TRUNOV, ANTON P. DANILENKO, YULIA V. STEPENKO, GALINA A. BATISCHEVA, PAVEL A. GALENKO-YAROSHEVSKIY
Abstract: Introduction: Experimental and clinical data accumulated over the past decade indicate a number of pleiotropic effects that are inherent in incretinomimetics. These effects are due to the wide distribution of GLP-1 receptors (GLP-1R) in many organs and tissues. Objective: Study of hepatoprotective activity of exenatide and vildagliptin on the liver ischemia/reperfusion model, taking into account biochemical and morphological parameters. Methods: Ischemia-reperfusion injury of the liver was reproduced by 15-minute clamping of the rat liver-duodenal ligament analogue with subsequent restoration of blood flow and removal of the animal from the experiment on the 3rd day. Exenatide at a dose of 10 µg/kg was administered subcutaneously, vildagliptin orally at a dose of 0.2 mg/kg 2 hours before the experiment. Results: Exenatide (10 µg/kg) and vildagliptin (0.2 mg/kg) reduced hepatocellular ischemia/reperfusion injury, which resulted in preventing the increased activity of AST and ALT transaminases, reducing necrosis areas by 1.9 times (compared with the ischemia/reperfusion group), reducing the infiltration of stromal and parenchymal elements of the liver, reducing edema. Conclusion: The hepatoprotective effects of exenatide and vildagliptin identify them as potentially effective drugs for correcting ischemic/reperfusion injury of the liver.
Keyword: Ischemia-reperfusion, liver, incretinomimetics, exenatide, vildagliptin, hepatoprotection
DOI: https://doi.org/10.31838/ijpr/2019.11.04.0307
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free